Hepatocellular carcinoma
Hepatocellular carcinoma
复制标题
DOI：
10.1097/00001574-200405000-00009
复制
发表时间：
2004-05-01
影响因子：
2.5
通讯作者：
Marrero, JA
中科院分区：
文献类型：
--
作者：
Lopez, LJ;Marrero, JA
综述目的随着肝癌的发病率和认知度的提高，今年肝细胞癌（HCC）的论文发表量与去年相比继续增加。最近的研究结果分子钟研究表明，丙型肝炎相关的HCC将在未来20年内继续增加，类似于日本的流行病。非酒精性脂肪肝是美国最常见的慢性肝病，与HCC相关。肥胖已被证明是HCC发展的重要危险因素。磷脂酰肌醇蛋白聚糖-3被证明能够区分肝硬化和HCC，因此有可能成为一种新的肿瘤标志物。动态钆MRI是评价HCC的首选成像。肝移植仍然是HCC的首选治疗方法。然而，在非手术肝细胞癌经动脉化疗栓塞和射频消融已被证明，以提高survival.Summary作为肝细胞癌的发病率继续增加，确定那些在发展这种肿瘤的风险是至关重要的。因此，肥胖作为一个重要的危险因素和磷脂酰肌醇蛋白聚糖-3作为一个潜在的肿瘤的发现突出了这种肿瘤的早期检测的显着进展，因此可以应用肝移植和化疗栓塞等治疗。
Purpose of review This year the number of papers published regarding hepatocellular carcinoma (HCC continued to increase compared with last year, coinciding with an increase in incidence and awareness of this tumor.Recent findings Molecular clock studies determined that hepatitis C-related HCC will continue to increase over the next 20 years mimicking the Japanese epidemic. Non-alcoholic fatty liver disease, the most common chronic liver disease in the US, has been associated with HCC. Obesity has been shown to be an important risk factor for the development of HCC. Glypican-3 was shown to be able to discriminate between cirrhosis and HCC, and therefore has the potential to be a novel tumor marker. Dynamic gadolinium MRI is the preferred imaging of choice for the evaluation of HCC. Liver transplantation continues to be the preferred treatment of HCC. However, in nonsurgical HCC transarterial chemoembolization and radiofrequency ablation have been shown to improve survival.Summary As the incidence of HCC continues to increase, identifying those at risk for developing this tumor is of paramount importance. Therefore, the findings of obesity as an important risk factor and Glypican-3 as a potential tumor highlight significant advances for the early detection of this tumor so therapies, such as liver transplantation and chemoembolization, can be applied.